JPMorgan Reinstates Stoke Therapeutics (STOK) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts STOK Hot Sheet
Price: $26.13 +2.63%
Rating Summary:
14 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Rating Summary:
14 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on Stoke Therapeutics (NASDAQ: STOK) with a Neutral rating and a price target of $6.00.
For an analyst ratings summary and ratings history on Stoke Therapeutics click here. For more ratings news on Stoke Therapeutics click here.
Shares of Stoke Therapeutics closed at $4.22 yesterday.
You May Also Be Interested In
- Roth/MKM Starts Dianthus Therapeutics (DNTH) at Buy
- Stephens Starts Mama’s Creations (MAMA) at Overweight
- Piper Sandler Assumes Delek US (DK) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
